ClinicalTrials.gov
ClinicalTrials.gov Menu

Genotypes and Phenotypes in Pediatric SIRS and Sepsis (GAPPSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02728401
Recruitment Status : Completed
First Posted : April 5, 2016
Last Update Posted : April 19, 2018
Sponsor:
Collaborator:
Immunexpress
Information provided by (Responsible Party):
Jerry Zimmerman, Seattle Children's Hospital

Brief Summary:
The aim of this investigation is to longitudinally quantify host gene expression and serum proteins in children with infectious and non-infectious SIRS. The investigators hypothesize that children with non-infectious SIRS, with bacterial infection associated SIRS, or with viral infection associated SIRS will exhibit distinct patterns of host gene expression and serum proteins. The investigators further hypothesize that it should be possible to discover sets of mRNA or protein biomarkers that will permit unambiguous diagnosis of non-infectious SIRS, SIRS associated with bacterial infection, and SIRS associated with viral infection.

Condition or disease
Systemic Inflammatory Response Syndrome (SIRS) Sepsis

Detailed Description:

The investigators will undertake a proof-of-concept, pilot, prospective, observational trial that aims to recruit ~90 children from the Seattle Children's Hospital Pediatric Intensive Care Unit (PICU) and Cardiac Intensive Care Unit (CICU). The study will plan to recruit 30 children who are scheduled for surgery to repair congenital cardiac malformations, 15 - 25 immunocompetent children with culture positive sepsis, and 15 - 25 immunocompromised children with culture positive sepsis, and 30-40 children who are polymerase chain reaction (PCR) positive for viral respiratory pathogens (RSV, influenza, parainfluenza, rhinovirus, etc), and who meet the eligibility criteria. In total, accounting for culture negative bacterial sepsis (estimated 40%), the investigators plan to enroll 50 children with sepsis, 30-40 with viral sepsis, and 20 children undergoing surgery for congenital heart disease.

Demographic data will be collected at the time of ICU admission. Illness severity will be quantified by PRISM III and day 1 PELOD scores. Additional measures of sepsis severity will include oxygenation index, saturation index and duration of mechanical ventilation, vasoactive inotropic score and duration of vasoactive-inotropic support and highest serum creatinine on day 1. Resource utilization will be measured as PICU and hospital duration of stay.

For all children enrolled in the study, blood samples will be obtained on study days 1, 2 and 3. For children with sepsis, if cultures remain sterile or PCR negative, no additional research blood samples will be obtained. For children with sepsis and a positive culture or positive PCR by study day 3, additional blood samples will be obtained on the day of PICU discharge.


Study Type : Observational
Actual Enrollment : 104 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Genotypes and Phenotypes in Pediatric SIRS and Sepsis (GAPPSS)
Actual Study Start Date : May 1, 2013
Actual Primary Completion Date : December 31, 2017
Actual Study Completion Date : December 31, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Group/Cohort
INSI
Infection-negative systemic inflammation (INSI). The INSI group consists of children who have undergone congenital cardiac defect corrective surgery requiring cardiopulmonary bypass, known to induce an INSI response for ~24 hours thereafter; all children in this cohort are culture negative. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
CSSS
Clinical severe sepsis syndrome (CSSS). Children assigned to the CSSS group had confirmed or highly suspected infection (microbial culture orders, antimicrobial prescription), exhibited 2 or more systemic inflammatory response syndrome criteria (including temperature and leukocyte criteria), and demonstrated at least cardiovascular ± pulmonary organ dysfunction. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
Viral
The Viral Infection group consists of children who displayed signs and symptoms of severe viral infection, and who tested positive for respiratory viral infection(s) by a molecular virus panel test. These children were clinically evaluated to not have bacterial sepsis. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).



Primary Outcome Measures :
  1. Gene Expression Levels [ Time Frame: Day 1 of admission to the pediatric intensive care unit (PICU) ]
    Gene expression levels (quantitative) will be compared between CSSS, INSI and viral infection groups, in a search for signatures that can discriminate these groups


Secondary Outcome Measures :
  1. Serum Protein Expression Profiles [ Time Frame: Day 1 of admission to the pediatric intensive care unit (PICU) ]
    Serum protein expression profiles (semi-quantitative) will be compared between CSSS and INSI groups, in a search for signatures that can discriminate the two groups


Biospecimen Retention:   Samples With DNA
Type 1: whole blood (2.5 mL) collected daily into PAXgene Blood RNA tube (PreAnalytiX, Ref # 7621650). Type 2: whole blood (1 mL) collected daily into serum separation tube (BD Vacutainer SST™ Tube with Silica Clot Activator, Polymer Gel, Silicone-Coated Interior, Ref # 367983). Type 3: whole blood (1 mL) collected on day 1 into lavender top Vacutainer (BD Vacutainer, lavender top, K2 EDTA 7.2mg, Ref # 367861).


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   38 Weeks to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

INSI group: children who had congenital cardiac defect corrective surgery requiring cardiopulmonary bypass, known to induce an INSI response for ~24 hours thereafter. All children in this group were immune competent and culture negative.

CSSS group: children with confirmed or highly suspected infection (microbial culture orders, antimicrobial prescription), SIRS criteria (including fever/hypothermia and leukocytosis/leukopenia), and at least cardiovascular ± pulmonary organ dysfunction.

Viral Infection group: children with severe respiratory dysfunction in the presence of PCR -documented viral infection.

Criteria

A. INSI group: systemic inflammation, in the absence of culture positive infection. Cardiac surgery patients, n=30.

Inclusion Criteria:

  • Admission to the CICU AND
  • Age ~1-18 years AND
  • Weight exceeding 10 kg
  • Vascular catheter capable of providing the blood draw or anticipated orders for venipuncture for clinical labs AND
  • Status post open heart surgery requiring cardiopulmonary bypass AND
  • Parents speak English AND
  • Not previously enrolled in the GAPPSS investigation

Exclusion Criteria:

  • Pre- or post-operative culture positive infection OR
  • Not expected to survive the CICU stay OR
  • Ward of the state OR
  • Concurrent malignancy or autoimmune disorder

B. CSSS (Clinical Severe Sepsis Syndrome) group: systemic inflammation, in the presence of highly suspected or documented bacterial infection. Children with clinical severe sepsis, n = 40. In this group, the investigators will enroll children who are immunocompetent as well as children who are immunocompromised.

Inclusion Criteria:

  • Admitted to the PICU AND
  • Age newborn (>38 weeks EGA)-18 years AND
  • Weight equal to or greater than 4 kg AND
  • Vascular catheter capable of providing the blood draw or anticipated orders for venipuncture for clinical labs AND
  • At least one organ dysfunction (severe sepsis) AND
  • Parents speak English AND
  • SIRS (systemic inflammatory response syndrome) AND
  • Strongly suspected or documented source of infection
  • Not previously enrolled in the GAPPSS investigation

Exclusion Criteria:

  • PICU nosocomial primary infection accounting for the sepsis event
  • Not expected to survive the PICU stay
  • Ward of the state

C. Viral Infection group. Severe respiratory dysfunction in the presence of PCR -documented viral infection. Children with clinical severe viral sepsis, n=6. In this group, the investigators will enroll children who are immunocompetent as well as children who are immunocompromised.

Inclusion Criteria:

  • Admitted to the PICU AND
  • Age newborn (>38 weeks EGA)-18 years AND
  • Weight equal to or greater than 4 kg AND
  • Vascular catheter capable of providing the blood draw or anticipated orders for venipuncture for clinical labs AND
  • Parents speak English AND
  • Severe respiratory dysfunction requiring invasive or non-invasive positive pressure mechanical ventilation support AND
  • Positive PCR verifying a viral infection
  • Not previously enrolled in the GAPPSS investigation

Exclusion Criteria:

  • PICU nosocomial primary infection accounting for the sepsis event
  • Not expected to survive the PICU stay
  • Ward of the state

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02728401


Locations
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Seattle Children's Hospital
Immunexpress
Investigators
Principal Investigator: Jerry J Zimmerman, MD, PhD Seattle Children's Hospital

Publications of Results:
Other Publications:
Responsible Party: Jerry Zimmerman, Professor of Pediatrics and Anesthesiology, Faculty in Pediatric Critical Care Medicine, University of Washington School of Medicine, Seattle Children's Hospital
ClinicalTrials.gov Identifier: NCT02728401     History of Changes
Other Study ID Numbers: 14761
First Posted: April 5, 2016    Key Record Dates
Last Update Posted: April 19, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The investigators plan to publish the results of the GAPPSS study in a peer-reviewed scientific journal. A supplemental digital file associated with this paper will be made publicly available through a web link, and will contain relevant clinical data (with all patients de-identified).

Keywords provided by Jerry Zimmerman, Seattle Children's Hospital:
inflammation
sepsis
pediatric
transcripts
serum proteins
cardiopulmonary bypass

Additional relevant MeSH terms:
Sepsis
Toxemia
Systemic Inflammatory Response Syndrome
Infection
Inflammation
Pathologic Processes
Shock